Unfortunately, there are a lot of assertions floating around that tell a misleading story about pharmaceutical manufacturing, diminishing America’s leadership and suggesting our reliance on other countries has put us at risk of potential shortages. In reality, a lot of manufacturing occurs right here in the United States.
The biopharmaceutical industry has a robust, growing presence in the United States – especially when it comes to manufacturing. Because of its large supply chain, the biopharmaceutical industry supports more than 4 million jobs across the United States, directly employing more than 811,000 Americans. Of those jobs, nearly 120,000 are high-wage manufacturing jobs, which is double the percentage of manufacturing jobs compared to the private sector overall. In 2017, wages for biopharmaceutical manufacturing jobs were 72% greater than the average wage for all U.S. manufacturing jobs.
Biopharmaceutical manufacturing jobs are housed at more than 1,300 facilities across the United States, contributing to the national economy and local economies – and investments in these facilities continues to grow.
Between 2000 and 2016, biopharmaceuticals outpaced all other manufacturing sectors in U.S. economic output growth. And in the past two years, biopharmaceutical companies have announced plans to invest more than $27 billion in the United States, including new manufacturing plants.
Part of ensuring the stability of our manufacturing supply chain is geographic diversity, which includes a robust manufacturing presence in the United States. We cannot overlook just how much manufacturing happens here and the economic impact that has on our economy. Discussions about enabling more manufacturing in the United States are important, but let’s not forget that the United States already sustains a substantial manufacturing presence that is part of a larger global network. We cannot replace all global manufacturing with solely U.S. manufacturing without upsetting the entire biopharmaceutical supply chain to the detriment of patients.
Nicole Longo
Nicole Longo is Deputy Vice President of public affairs at PhRMA focusing on Medicare, 340B, importation and more. She previously worked for a D.C.-based public affairs firm where she assisted a wide range of clients with communications efforts on everything from trade policy to agriculture policy to health care policy. Outside the office, Nicole can be found trying new restaurants (usually Italian), taking an occasional barre class and cheering on the Cincinnati Bengals.
Nicole Longo
Staffing up: Building the future biopharma workforce to keep America in the lead
MFN price controls threaten American jobs and the U.S. economy
America Cures: Championing U.S. leadership in medical innovation
Middlemen mark up drug prices and keep discounts meant for you
Celebrating STEM Day: Investing in America’s innovators
Manufacturing U.S. jobs and breakthroughs
Historic biopharmaceutical investments: A prescription for America’s future
The biopharmaceutical industry is one of the highest contributors to America’s economy among all manufacturers
Strong Trade Policies Protect American Workers and Biopharmaceutical Innovation
New research: Industry sponsored clinical trials contribute billions to state economies
Industry-backed STEM programs have supported 111 million students and nearly 183,000 teachers
Biopharmaceutical industry supports jobs and drives economic growth across the United States
Biden Administration’s Indo Pacific trade dialogue is a missed opportunity to bolster American exports, innovation
The Biden Administration has failed to advance an inclusive, worker-centered trade agenda
New data: America is an API powerhouse
Biopharmaceutical manufacturing companies continue to expand their economic footprint across the United States
Four ways that America’s biopharmaceutical industry supports jobs and fuels economic growth
U.S. biopharmaceutical exports support jobs, innovation
ICYMI: New research builds upon growing body of evidence on value of COVID-19 treatments and vaccines
The Senate’s latest price setting proposal will undermine U.S. economic growth
ICYMI: A patient, physician, biotech investor and industry leaders warn about the dangers of government price setting bill
PhRMA member companies’ R&D investments reach record high of $102.3 billion in 2021
Putting patients first at the state level — A conversation with Mark Reisenauer, President of Astellas Pharma US
COVID-19 vaccines and treatments helped save millions of lives and billions in health care costs
Biopharmaceutical industry drives economic growth in all 50 states
New Data: COVID-19 vaccine global production capacity projected to exceed 20 billion doses this year
New report highlights importance of IP-intensive manufacturing industries to the U.S. economy
PhRMA member companies’ R&D investments reach record high of $91.1 billion in 2020
Data shows COVID-19 vaccines are creating a pathway to a strong U.S. recovery
Intellectual property is the key to vaccine development, manufacturing and technology sharing
Beyond output and employment: The impact of America’s biopharmaceutical industry
Preserving U.S. innovation worldwide is more important than ever
American biopharmaceutical manufacturing: Fueling economic growth now and for years to come
Manufacturing Day 2020: A closer look at the biopharmaceutical industry’s contributions
Guest Post: How proactivity and planning helped Novartis ensure a stable supply of medicines during COVID-19
By the numbers: A look at the sourcing of API used in medicines consumed in the United States
Stakeholders raise concerns with proposed drastic changes to the pharmaceutical supply chain
It’s a good thing pharmaceutical manufacturing supply chains are spread out around the world
Setting up a pharmaceutical manufacturing supply chain is a complex and lengthy process
New report: Biopharmaceutical industry supports over 4 million jobs and $1.1 trillion in U.S. economic output
What you need to know about H.R. 3
New poll: 76% of voters concerned Speaker Pelosi’s plan would result in fewer new medicines
IP Explained: By the Numbers: How reliable IP protections promote a strong U.S. economy
What they are saying: Negative impact of Pelosi’s plan on biopharmaceutical innovation
Pelosi’s radical plan leaves lung cancer patients behind
Event tomorrow: Maintaining America’s leadership in access and innovation
Pelosi’s radical plan would leave Alzheimer’s patients behind
What they are saying: Broad opposition to Pelosi’s radical drug pricing plan
On Manufacturing Day, a closer look at the biopharmaceutical sector’s contributions
By the Numbers: Pelosi’s radical plan puts America’s economy and jobs at risk
World Trade Month: How we can expand world-class pro-innovation standards
New Report: Advanced manufacturing powering innovative biopharmaceuticals
Clinical trials impact state economies
Biopharmaceutical venture capital is spurring innovation and economic growth
PhRMA member companies R&D investments hit record high in 2017 - $71.4 billion
Researchers bring focus on science and medicine to California’s capital city
To continue to drive the innovation economy and exports, American biopharmaceutical sector depends on fair trade agreements
New Report: America's biopharmaceutical industry supports 4.7 million jobs
Biopharma leads sustained economic growth driven by IP-intensive industries
New PhRMA resources chock full of biopharma industry facts
New medicines are part of the solution to hold down future health care costs
America’s global leadership in biopharmaceutical manufacturing
Economic Impact
Manufacturing
America’s global leadership in biopharmaceutical manufacturing
America’s global leadership in biopharmaceutical manufacturing